245 related articles for article (PubMed ID: 18514370)
1. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.
Boberg A; Gaunitz S; Bråve A; Wahren B; Carlin N
Vaccine; 2008 Sep; 26(40):5079-82. PubMed ID: 18514370
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
[TBL] [Abstract][Full Text] [Related]
3. Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
Starodubova E; Boberg A; Ivanov A; Latyshev O; Petrakova N; Kuzmenko Y; Litvina M; Chernousov A; Kochetkov S; Karpov V; Wahren B; Isaguliants MG
Vaccine; 2010 Feb; 28(8):1975-86. PubMed ID: 20188253
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR.
Matoba N; Kajiura H; Cherni I; Doran JD; Bomsel M; Fujiyama K; Mor TS
Plant Biotechnol J; 2009 Feb; 7(2):129-45. PubMed ID: 19037902
[TBL] [Abstract][Full Text] [Related]
5. Production of a recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes.
Yuki Y; Hara-Yakoyama C; Guadiz AA; Udaka S; Kiyono H; Chatterjee S
Biotechnol Bioeng; 2005 Dec; 92(7):803-9. PubMed ID: 16142801
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
Starodubova ES; Boberg A; Litvina M; Morozov A; Petrakova NV; Timofeev A; Latyshev O; Tunitskaya V; Wahren B; Isaguliants MG; Karpov VL
Vaccine; 2008 Sep; 26(40):5170-6. PubMed ID: 18468738
[TBL] [Abstract][Full Text] [Related]
8. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins.
Cruz LJ; Cabrales A; Iglesias E; Aguilar JC; González LJ; Reyes O
Int Immunopharmacol; 2009 Nov; 9(12):1452-9. PubMed ID: 19747570
[TBL] [Abstract][Full Text] [Related]
10. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
[TBL] [Abstract][Full Text] [Related]
11. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
[TBL] [Abstract][Full Text] [Related]
12. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
Bråve A; Hallengärd D; Schröder U; Blomberg P; Wahren B; Hinkula J
Vaccine; 2008 Sep; 26(40):5075-8. PubMed ID: 18450334
[TBL] [Abstract][Full Text] [Related]
13. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
[TBL] [Abstract][Full Text] [Related]
14. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.
Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T
Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice.
Van der Heijden PJ; Bianchi AT; Dol M; Pals JW; Stok W; Bokhout BA
Immunology; 1991 Jan; 72(1):89-93. PubMed ID: 1705237
[TBL] [Abstract][Full Text] [Related]
16. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
[TBL] [Abstract][Full Text] [Related]
17. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
Bckström M; Holmgren J; Schödel F; Lebens M
Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
[TBL] [Abstract][Full Text] [Related]
18. Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses.
Bråve A; Hallengärd D; Malm M; Blazevic V; Rollman E; Stanescu I; Krohn K
Vaccine; 2009 Jan; 27(2):184-6. PubMed ID: 18992294
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and virulence of attenuated vaccinia virus Tian Tan encoding HIV-1 muti-epitope genes, p24 and cholera toxin B subunit in mice.
Du S; Wang Y; Liu C; Wang M; Zhu Y; Tan P; Ren D; Li X; Tian M; Yin R; Li C; Jin N
J Virol Methods; 2015 Jul; 219():1-9. PubMed ID: 25796990
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of autoimmune diabetes by nasal administration of tandem glutamic acid decarboxylase 65 peptides.
Wang H; Yang J; Jin L; Feng J; Lu Y; Sun Y; Li T; Cao R; Wu J; Fan H; Liu J
Immunol Invest; 2009; 38(8):690-703. PubMed ID: 19860582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
